FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387249985> ?p ?o ?g. }

• W4387249985 endingPage "A14" @default.
• W4387249985 startingPage "A9" @default.
• W4387249985 abstract "SESSION TITLE: Allergy and Airway Posters 1 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/10/2023 12:00 pm - 12:45 pm PURPOSE: Obesity is associated with an increased asthma incidence and severity of symptoms, and a reduced response to treatment. Proinflammatory cytokines and mediators secreted by adipose tissue may promote the development and exacerbation of asthma in patients who are obese. Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in asthma pathogenesis. In the phase 3 NAVIGATOR study (NCT03347279) and the DESTINATION extension study (NCT03706079), tezepelumab reduced exacerbations and improved lung function, asthma control and health-related quality of life compared with placebo in patients with severe, uncontrolled asthma. This post hoc analysis assessed the long-term efficacy of tezepelumab in patients from NAVIGATOR and DESTINATION, according to baseline body mass index (BMI). METHODS: DESTINATION was a phase 3, multicenter, randomized, placebo-controlled, double-blind, extension study of patients with severe, uncontrolled asthma (12–80 years old) included in NAVIGATOR. Patients previously randomized to tezepelumab 210 mg every 4 weeks for 52 weeks continued treatment. Those previously randomized to placebo were re-randomized 1:1 to tezepelumab or placebo. In this analysis, the annualized asthma exacerbation rate (AAER) was assessed over 104 weeks in patients who received at least one dose of tezepelumab or placebo in NAVIGATOR, grouped by baseline BMI (healthy, < 25 kg/m2; overweight, 25 to < 30 kg/m2; or obese, ≥ 30 kg/m2). Weight change was assessed in patients who received tezepelumab in NAVIGATOR and DESTINATION or placebo in NAVIGATOR and DESTINATION. RESULTS: Among placebo recipients (n = 531), the AAER over 104 weeks was higher in those with a higher BMI (< 25 kg/m2: 1.78 [95% confidence interval (CI): 1.44–2.21]; 25 to < 30 kg/m2: 1.87 [95% CI: 1.48–2.37]; ≥ 30 kg/m2: 2.16 [95% CI: 1.74–2.69]). Tezepelumab (n = 528) reduced the AAER over 104 weeks compared with placebo by 58% (95% CI: 42–70), 59% (95% CI: 43–70) and 57% (95% CI: 42–68) in patients with a BMI of < 25 kg/m2, 25 to < 30 kg/m2 and ≥ 30 kg/m2, respectively. In patients who received tezepelumab only (n = 389) or placebo only (n = 197) in both NAVIGATOR and DESTINATION, the mean (standard deviation [SD]) increases in BMI from baseline to week 104 were 0.20 kg/m2 (2.03) and 0.43 kg/m2 (2.57), respectively, and the mean (SD) increases in weight from baseline to week 104 were 0.75 kg (5.81) and 1.27 kg (7.10), respectively. CONCLUSIONS: Tezepelumab treatment reduced asthma exacerbations over 2 years irrespective of baseline BMI. CLINICAL IMPLICATIONS: This analysis demonstrates the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled asthma, including those with BMI in the healthy, overweight or obese ranges. DISCLOSURES: Employee relationship with AstraZeneca Please note: >$100000 by Christopher Ambrose, value=Salary Consultant relationship with AstraZeneca Please note: years by Geoffrey Chupp, value=Consulting fee Consultant relationship with RAPT therapeutics Please note: 2022 Added 03/31/2023 by Geoffrey Chupp, source=Web Response, value=Consulting fee Advisor/Speaker/consultant relationship with Amgen Please note: years by Geoffrey Chupp, value=Honoraria Advisor/Speaker/consultant relationship with Regeneron Please note: years by Geoffrey Chupp, value=Honoraria Consultant relationship with GlaxoSmithKline Please note: years by Geoffrey Chupp, value=Consulting fee Consultant relationship with Novartis Please note: years by Geoffrey Chupp, value=Consulting fee Consultant relationship with Sanofi-Genzyme Corporation Please note: years by Geoffrey Chupp, value=Consulting fee Consultant relationship with Genentech Please note: years by Geoffrey Chupp, value=Consulting fee Consultant relationship with Boehringer Ingelheim Please note: years by Geoffrey Chupp, value=Consulting fee No relevant relationships by Kaitlyn Lawson Employee relationship with Amgen, Inc. Please note: 8/2020 to present by Andrew Lindsley, value=Salary and stock Advisory Committee Member relationship with Regeneron Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Research relationship with TEVA Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Consultant relationship with Avillion Please note: May-Dec 2022 Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Advisory Committee Member relationship with Amgen Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Grant support relationship with SANOFI Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Advisory Committee Member relationship with SANOFI Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Grant support relationship with AstraZeneca Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Scientific Medical Advisor relationship with AstraZeneca Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Advisory Committee Member relationship with AstraZeneca Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Research relationship with Novartis Please note: Ended 08/2022 Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Research relationship with Genentech Please note: Ended 09/2022 Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Advisory Committee Member relationship with Genentech Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Honoraria Advisory Committee Member relationship with TEVA Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Speaking with my own content relationship with GSK Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Grant fees relationship with Regeneron Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Scientific Medical Advisor relationship with SANOFI Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Speaker with my own slides relationship with AstraZeneca Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Grant support relationship with Avillion Please note: 2019-2022 Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Advisory Committee Member relationship with TEVA Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Grants relationship with TEVA Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Consultant relationship with TEVA Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Grant fees relationship with Novartis Please note: 2020-2022 Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Grants relationship with Genentech Please note: 2021-2022 Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Grants relationship with Janssen Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Grants relationship with SANOFI Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Advisory Committee Member relationship with Genentech Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Advisory Committee Member relationship with GSK Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Honoraria Grants relationship with GSK Please note: Ongoing Added 06/07/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Advisory Committee Member relationship with Amgen Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Honoraria Consultant relationship with Avillion Please note: May 2022-Dec 2022 Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Clinical trial funding for institution relationship with AstraZeneca, Genentech, GSK, Regeneron, Sanofi, TEVA, Gossamer and Avillion Please note: >24 months by Njira Lugogo, value=Grant/Research Support Advisory Committee Member relationship with AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi, Teva and Amgen Please note: >24 months by Njira Lugogo, value=Consulting fee Consultant relationship with AstraZeneca, TEVA, Avillion, GSK Please note: >24 months Added 10/25/2022 by Njira Lugogo, value=Consulting fee Funds for developing CME presentations relationship with AKH, Medscape and NACE Please note: >24 months by Njira Lugogo, value=Grant/Research Support Research money received by institution relationship with Janssen Please note: 08/2020 - Present by Njira Lugogo, value=Grant/Research Scientific Medical Advisor relationship with AstraZeneca Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Advisory Committee Member relationship with AstraZeneca Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Not Speaker's Bureau relationship with AstraZeneca Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Travel Advisory Committee Member relationship with GSK Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Consultant relationship with GSK Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with GSK Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with GSK Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Travel Advisory Committee Member relationship with SANOFI/Regeneron Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Scientific Medical Advisor relationship with Regeneron Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Advisory Committee Member relationship with Amgen Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Consultant relationship with Avillion Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Advisory Committee Member relationship with Genentech Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Scientific Medical Advisor relationship with TEVA Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Scientific Medical Advisor relationship with AstraZeneca Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Honoraria Consultant relationship with AstraZeneca Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Not Speaker's Bureau relationship with AstraZeneca Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Honoraria Advisory Committee Member relationship with SANOFI/Regeneron Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Honoraria Research relationship with SANOFI/Regeneron Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Research relationship with AstraZeneca Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Advisory Committee Member relationship with GSK Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Honoraria Scientific Medical Advisor relationship with Amgen Please note: Ongoing Added 03/27/2023 by Njira Lugogo, source=Web Response, value=Honoraria Research relationship with GSK Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Grant/Research Support Not Speaker's Bureau relationship with GSK Please note: Ongoing Added 04/09/2023 by Njira Lugogo, source=Web Response, value=Consulting fee Employee relationship with Astrazeneca Please note: 1/1/2022- present Added 03/15/2023 by Joe Spahn, source=Web Response, value=Salary Removed 03/15/2023 by Joe Spahn, source=Web Response stock optioons relationship with astrazeneca Please note: 1/1/2022 to present Added 03/21/2023 by Joe Spahn, source=Web Response, value=stock options Consultant relationship with Om pharma Please note: 2022 Added 12/01/2022 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Phylaxis Please note: 2022 Added 12/01/2022 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Amgen AstraZeneca Avalo Therapeutics Boehringer Ingelheim Please note: 2021-2023 Added 03/15/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Cerecor Cohero Health Cytoreason Eli Lilly Equillium Please note: 2021-2023 Added 03/15/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Glaxosmithkline Incyte Kinaset Merck Novartis Om Pharma Please note: 2021-2023 Added 03/15/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Overtone Therapeutics/Foresite Labs Phylaxis pulmatrix Please note: 2021-2023 Added 03/15/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Rapt Therapeutics Regeneron Restorbio Roche/Genentech Sanofi Please note: 2021-2023 Added 03/15/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Sentien Sound Bio Tetherex Pharmaceuticals Teva upstream Please note: 2021-2023 Added 03/15/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Research grants relationship with National Institute of Allergy and Infectious Diseases Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Grant/Research Support Research grants relationship with The National Heart, Lung, and Blood Institute Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Grant/Research Support Consultant relationship with GSK Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Genentech Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Sanofi Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Personal fees relationship with AstraZeneca Please note: years by Michael Wechsler, value=Honoraria Consultant relationship with Regeneron Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with AstraZeneca Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Teva Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Novartis Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Boehringer Ingelheim Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Sentien Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Equillium Please note: N/A Added 03/31/2023 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Rapt therapeutics Please note: 2022 Added 12/01/2022 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Astrazeneca Please note: 2+ years by Michael Wechsler, value=Consulting fee Consultant relationship with Amgen Please note: 2+ years by Michael Wechsler, value=Consulting fee Consultant relationship with Sanofi Please note: 2+ years by Michael Wechsler, value=Consulting fee Consultant relationship with GlaxoSmithKline Please note: 2+ years by Michael Wechsler, value=Grant/Research Support Consultant relationship with Regeneron Please note: 2+years by Michael Wechsler, value=Consulting fee Board Member relationship with Sentien Please note: 2+ years by Michael Wechsler, value=Consulting fee Consultant relationship with Boehringer Ingelheim Please note: 2+ years by Michael Wechsler, value=Consulting fee Advisory Committee Member relationship with incyte Please note: 2+ years by Michael Wechsler, value=Consulting fee Board Member relationship with Cytoreason Please note: 2+ years by Michael Wechsler, value=Consulting fee Personal fees relationship with Teva Please note: years by Michael Wechsler, value=Honoraria Personal fees relationship with GSK Please note: years by Michael Wechsler, value=Honoraria Personal fees relationship with Novartis Please note: years by Michael Wechsler, value=Honoraria Personal fees relationship with Sanofi Please note: years by Michael Wechsler, value=Honoraria Personal fees relationship with Regeneron Please note: years by Michael Wechsler, value=Honoraria Personal fees relationship with Boehringer Ingelheim Please note: years by Michael Wechsler, value=Honoraria Personal fees relationship with Genzyme Please note: years by Michael Wechsler, value=Honoraria Personal fees relationship with Equillium Please note: years by Michael Wechsler, value=Honoraria Consultant relationship with Cohero Health Please note: years by Michael Wechsler, value=Consulting fee Consultant relationship with Amgen Please note: 2020- by Michael Wechsler, value=Honoraria Consultant relationship with Upstream Bio Please note: 2022 Added 12/01/2022 by Michael Wechsler, source=Web Response, value=stock options Consultant relationship with tetherex Please note: 2022 Added 12/01/2022 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Sound Biologics Please note: 2022 Added 12 /01 /2022 by Michael Wechsler, source=Web Response, value=Consulting Consultant relationship with Kinaset Please note: 2022 Added 12/01/2022 by Michael Wechsler, source=Web Response, value=Consulting fee Consultant relationship with Avalo Please note: 2022 Added 12/01/2022 by Michael Wechsler, source=Web Response, value=Consulting fee" @default.
• W4387249985 created "2023-10-03" @default.
• W4387249985 creator A5006060250 @default.
• W4387249985 creator A5013242651 @default.
• W4387249985 creator A5026781408 @default.
• W4387249985 creator A5036653584 @default.
• W4387249985 creator A5037741829 @default.
• W4387249985 creator A5068993336 @default.
• W4387249985 creator A5069459248 @default.
• W4387249985 date "2023-10-01" @default.
• W4387249985 modified "2023-10-03" @default.
• W4387249985 title "LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX" @default.
• W4387249985 doi "https://doi.org/10.1016/j.chest.2023.07.075" @default.
• W4387249985 hasPublicationYear "2023" @default.
• W4387249985 type Work @default.
• W4387249985 citedByCount "0" @default.
• W4387249985 crossrefType "journal-article" @default.
• W4387249985 hasAuthorship W4387249985A5006060250 @default.
• W4387249985 hasAuthorship W4387249985A5013242651 @default.
• W4387249985 hasAuthorship W4387249985A5026781408 @default.
• W4387249985 hasAuthorship W4387249985A5036653584 @default.
• W4387249985 hasAuthorship W4387249985A5037741829 @default.
• W4387249985 hasAuthorship W4387249985A5068993336 @default.
• W4387249985 hasAuthorship W4387249985A5069459248 @default.
• W4387249985 hasBestOaLocation W43872499851 @default.
• W4387249985 hasConcept C111368507 @default.
• W4387249985 hasConcept C121332964 @default.
• W4387249985 hasConcept C126322002 @default.
• W4387249985 hasConcept C12725497 @default.
• W4387249985 hasConcept C127313418 @default.
• W4387249985 hasConcept C136764020 @default.
• W4387249985 hasConcept C2776042228 @default.
• W4387249985 hasConcept C2777382242 @default.
• W4387249985 hasConcept C2780221984 @default.
• W4387249985 hasConcept C41008148 @default.
• W4387249985 hasConcept C61797465 @default.
• W4387249985 hasConcept C62520636 @default.
• W4387249985 hasConcept C71924100 @default.
• W4387249985 hasConceptScore W4387249985C111368507 @default.
• W4387249985 hasConceptScore W4387249985C121332964 @default.
• W4387249985 hasConceptScore W4387249985C126322002 @default.
• W4387249985 hasConceptScore W4387249985C12725497 @default.
• W4387249985 hasConceptScore W4387249985C127313418 @default.
• W4387249985 hasConceptScore W4387249985C136764020 @default.
• W4387249985 hasConceptScore W4387249985C2776042228 @default.
• W4387249985 hasConceptScore W4387249985C2777382242 @default.
• W4387249985 hasConceptScore W4387249985C2780221984 @default.
• W4387249985 hasConceptScore W4387249985C41008148 @default.
• W4387249985 hasConceptScore W4387249985C61797465 @default.
• W4387249985 hasConceptScore W4387249985C62520636 @default.
• W4387249985 hasConceptScore W4387249985C71924100 @default.
• W4387249985 hasIssue "4" @default.
• W4387249985 hasLocation W43872499851 @default.
• W4387249985 hasOpenAccess W4387249985 @default.
• W4387249985 hasPrimaryLocation W43872499851 @default.
• W4387249985 hasRelatedWork W1971566616 @default.
• W4387249985 hasRelatedWork W2116002913 @default.
• W4387249985 hasRelatedWork W2217896115 @default.
• W4387249985 hasRelatedWork W2368601867 @default.
• W4387249985 hasRelatedWork W2930796516 @default.
• W4387249985 hasRelatedWork W315474250 @default.
• W4387249985 hasRelatedWork W3196921892 @default.
• W4387249985 hasRelatedWork W4310493648 @default.
• W4387249985 hasRelatedWork W4322724676 @default.
• W4387249985 hasRelatedWork W983083524 @default.
• W4387249985 hasVolume "164" @default.
• W4387249985 isParatext "false" @default.
• W4387249985 isRetracted "false" @default.
• W4387249985 workType "article" @default.